Halozyme Therapeutics HALO Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's other non-current liabilities?
- Halozyme Therapeutics (HALO) reported other non-current liabilities of $106.45M in Q1 2026.
- How has Halozyme Therapeutics's other non-current liabilities changed year-over-year?
- Halozyme Therapeutics's other non-current liabilities increased by 88.6% year-over-year, from $56.44M to $106.45M.
- What is the long-term trend for Halozyme Therapeutics's other non-current liabilities?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's other non-current liabilities has grown at a 101.1% compound annual growth rate (CAGR), from $3.47M to $113.86M.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.